A288330 Stock Overview
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide.
Bridge Biotherapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩10,700.00|
|52 Week High||₩16,250.00|
|52 Week Low||₩10,300.00|
|1 Month Change||-21.90%|
|3 Month Change||-7.36%|
|1 Year Change||-18.94%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-40.88%|
Recent News & Updates
|A288330||KR Biotechs||KR Market|
Return vs Industry: A288330 exceeded the KR Biotechs industry which returned -39.8% over the past year.
Return vs Market: A288330 underperformed the KR Market which returned -15.8% over the past year.
|A288330 Average Weekly Movement||6.2%|
|Biotechs Industry Average Movement||6.4%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.3%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A288330 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: A288330's weekly volatility (6%) has been stable over the past year.
About the Company
|2015||30||James Jungkue Lee||https://bridgebiorx.com|
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery.
Bridge Biotherapeutics Fundamentals Summary
|A288330 fundamental statistics|
Is A288330 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A288330 income statement (TTM)|
|Cost of Revenue||₩1.18b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.33k|
|Net Profit Margin||-1,365.70%|
How did A288330 perform over the long term?See historical performance and comparison
Is Bridge Biotherapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A288330's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A288330's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A288330 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.
PE vs Market: A288330 is unprofitable, so we can't compare its PE Ratio to the KR market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A288330's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A288330 is overvalued based on its PB Ratio (4.9x) compared to the KR Biotechs industry average (3.3x).
How is Bridge Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bridge Biotherapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Bridge Biotherapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: A288330 is currently unprofitable.
Growing Profit Margin: A288330 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A288330's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A288330's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A288330 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).
Return on Equity
High ROE: A288330 has a negative Return on Equity (-61.05%), as it is currently unprofitable.
How is Bridge Biotherapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: A288330's short term assets (₩44.4B) exceed its short term liabilities (₩3.6B).
Long Term Liabilities: A288330's short term assets (₩44.4B) exceed its long term liabilities (₩53.6M).
Debt to Equity History and Analysis
Debt Level: A288330 is debt free.
Reducing Debt: A288330 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A288330 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A288330 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 39.7% each year.
What is Bridge Biotherapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A288330's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A288330's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A288330's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A288330's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A288330 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
James Jungkue Lee
Mr. James Jungkue Lee serves as Chief Executive Officer and Director at Bridge Biotherapeutics Inc. Mr. Lee founded Bridge Biotherapeutics, Inc. in 2015. Mr. James Jungkue Lee served as the Vice President...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bridge Biotherapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Bridge Biotherapeutics, Inc.
- Ticker: A288330
- Exchange: KOSDAQ
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩211.929b
- Shares outstanding: 19.81m
- Website: https://bridgebiorx.com
Number of Employees
- Bridge Biotherapeutics, Inc.
- Building B, Innovalley
- Suite 903-2
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.